PROMACTA has been proven to help pediatric patients with chronic immune thrombocytopenia (ITP) reach target levels and maintain them for a long time

In a clinical trial of 67 pediatric patients with chronic ITP...


62% of patients reached their target platelet level (28 of 45), some as early as Week 1



In a clinical trial of 92 pediatric patients with chronic ITP...


41%of patients maintained a response at least 6 weeks (26 of 63)



13%of patients on PROMACTA® (eltrombopag) (6 of 45) needed to take rescue medication to raise their platelet levels compared with 50% of patients on placebo (11 of 22)


53%of patients taking other ITP medications were able to reduce or stop using them after starting PROMACTA (8 of 15)

See what others living with ITP prefer

Patients with ITP prefer once-daily oral dosing

The ITP World Impact Survey (I-WISh) was a global survey conducted in 13 countries with 1507 patients and 472 physicians. In the US alone, there were more than 500 patients. The survey asked about patient preference for administration. Here’s what it found:


  • Most patients, 87%, said they prefer treatment that could be taken by mouth once a day (over an injectable therapy or a twice-daily oral regimen)